Sitemap
- Home
- About
- Pipeline
- Platform
- Patients
- News
- Arsanis and X4 Pharmaceuticals Agree to Merger
- Clinical Data for X4P-001-IO in Combination with Inlyta® (Axitinib) Demonstrated Encouraging Overall Response Rates (including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma
- First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary Immunodeficiency Disease
- First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting
- First Clinical Data from Combination of X4P-001-IO and Keytruda® (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- First Data from Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the European Society of Medical Oncology 2017 Congress
- Initial Clinical Trial Data for Combination of X4P-001-IO and Inlyta® (Axitinib) Demonstrate Encouraging Disease Control Rates and Durable Clinical Responses in Patients with Clear Cell Renal Cell Carcinoma (ccRCC)
- Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome
- Updated Clinical Data from Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- X4 Pharmaceuticals and Collaborators Present Data that WHIM Syndrome is Underdiagnosed and Patients are Impacted by Broad Spectrum of Medical Complications
- X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-RD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease
- X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell
- X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals Announces Rare Disease Research Collaboration with Yale University
- X4 Pharmaceuticals Appoints Adam Mostafa as Chief Financial Officer
- X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer
- X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board of Directors
- X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors
- X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial
- X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO
- X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity
- X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism
- X4 Pharmaceuticals Presents Clinical Data Showing Combination of X4P-001 and Opdivo® (nivolumab) Improved Clinical Responses in RCC Patients Unresponsive to Opdivo Monotherapy
- X4 Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for X4P-001-RD for the Treatment of WHIM Syndrome
- X4 Pharmaceuticals Reports Positive Clinical Data from Phase 2 Expansion Study of X4P-001-IO and Axitinib in Patients with Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals Secures $27 Million in Series B Financing
- X4 Pharmaceuticals to Present at Cowen and Company Healthcare Conference
- X4 Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
- X4 Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
- X4 Pharmaceuticals to Present at Upcoming Investor Conferences
- X4 Pharmaceuticals to Present Clinical Data at Upcoming Oncology Medical Conferences
- X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM syndrome
- X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab)
- X4 Pharmaceuticals to Present Clinical Data Used to Determine Phase 3 Dose from Phase 2/3 Study of X4P-001-RD in WHIM Syndrome
- X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
- X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of X4P-001-RD in Patients with WHIM Syndrome
- POSTER: MDSC Trafficking and Function in RCC by CXCR4 in the Presence of a VEGF-R Antagonist is Dependent on HIF-2α Expression
- X4 Pharmaceuticals announces data presentation for lead candidate X4P-001 at AACR Annual Meeting
- X4 Pharmaceuticals Announces Formation of Corporate Advisory Board
- X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma
- X4 Pharmaceuticals announces new data for lead candidate X4P-001 in renal cell carcinoma at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
- X4 Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference
- X4 Pharmaceuticals to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference
- POSTER: Regulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist
- X4 Pharmaceuticals Announces FDA Allowance of X4P-001 IND for Phase 1b/2a Study of in Refractory Clear Cell Renal Cell Carcinoma
- X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing
- Careers
- Contact
- Terms of Use
- Privacy Policy
- Sitemap